# Safety and Efficacy of Doravirine, Tenofovir, Lamivudine (MK-1439A) in Participants Infected With Treatment-Naïve Human Immunodeficiency Virus (HIV) -1 With Transmitted Resistance (MK-1439A-030)

> **NCT02629822** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 10 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** Doravirine/lamivudine/tenofovir disoproxil fumarate

## Key facts

- **NCT ID:** NCT02629822
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-14
- **Primary completion:** 2018-11-28
- **Final completion:** 2020-10-28
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2021-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02629822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02629822, "Safety and Efficacy of Doravirine, Tenofovir, Lamivudine (MK-1439A) in Participants Infected With Treatment-Naïve Human Immunodeficiency Virus (HIV) -1 With Transmitted Resistance (MK-1439A-030)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02629822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*